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Abstract
Saccharomyces is a eukaryotic organism that possesses approximately 6,000 
known genes since 1996. It has long been used for food, bakeries, drinks, and 
therapeutics due to its many ingredients and its role in several mechanisms. 
Saccharomyces can be used as an experimental organism for medicinal products in 
the pharmaceutical industry. Particularly in public health, the use of Saccharomyces 
in the production of vaccines is remarkable. It has been alleviated that this yeast 
helps clarify the function of individual proteins in pathogenic viruses. To clarify 
virus life and host interactions, virus replication systems in Saccharomyces were 
interested in scientists. The new antiviral strategies with yeasts suggest the bio-
logical mechanism of a pathogen virus. Due to the variety of diseases and current 
epidemic conditions, these organisms play an essential role in prevention and 
treatment. This chapter will try to update Saccharomyces’ scientific discoveries with 
the most recent and up-to-date literature.
Keywords: Saccharomyces, pandemic diseases, experimental organisms,  
public health, antiviral strategies
1. Introduction
Besides poor treatment and vaccination programs, a healthy immune system 
and antioxidant mechanism are the essential defenders considering the current 
viral diseases. The viral diseases hosted in a body has several impacts on organs 
and systems. Also, long-term drug use or vaccination programs can cause some 
acute side effects on the body, such as gut microbiota, immunity, lung tissue, etc. 
Therefore, probiotics, prebiotics, vitamins, natural antioxidants have been gener-
ally recommended over the years. Probiotics named live microorganisms have 
beneficial effects on systems, and they have been used successfully. Prebiotics 
are non-digestible foods that stimulate intestinal tissue growth and modulate 
immunity. Vitamins, minerals, and natural antioxidants have been used to enhance 
immune activity and health in viral diseases. It can be said that all these supple-
ments are essential for adequate homeostasis.
Today, evaluate the most effective, economical, and safe vaccines is a significant 
challenge. Thus, some crucial organisms have been interested in vaccine production 
as well as nutrition. Among the different vaccination process, yeasts have a broad 
interest in the scientific area (Figure 1). These unicellular and saprotrophic fungi 
have been used as a biological model. They have also been accepted as critical models 
for experiments due to their cellular structure, components, and rapid growth. Yeast 
also can be cultured easily and manipulated genetically. These features showed that 
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yeasts are beneficial to identify the cellular mechanism of virus and vaccine pro-
grams safely [1, 2].
The yeast Saccharomyces, the essential eukaryotic organism, have been used as 
a biological model. Nevertheless, there is a notable gene homology in this yeast with 
human genes. In this chapter, we try to identify the Saccharomyces yeast as a useful 
model for biological experiments and observe the importance of viruses, viral 
diseases, and vaccines.
2. Saccharomyces
Saccharomyces cerevisiae is a model organism extensively used to investigate the 
biology of eukaryotic cells. It is widely used as a cell factory for producing pharma-
ceuticals, chemicals, and biofuels [3].
Saccharomyces, which is a genus belonging to the Saccharomyces fungus 
kingdom, includes many yeast species. The name of Saccharomyces is derived from 
the Latin words saccharo- (sugar) and - Greek mikes (mushrooms). These yeasts 
were initially suggested in 1680, and named Saccharomyces in 1837. A successful 
systemic concept on these higher eukaryotes was designed by Mayr [4]. Yeasts’ 
cultured forms have been used for thousands of years due to rapid reproduction and 
essential components. Typical features of Saccharomyces are the usage of nitrate 
and ability for the fermentation of carbohydrates. Saccharomyces have an excellent 
capacity for ethanol production, and they are suitable yeasts for large-scale fer-
mentation [5]. These important yeasts can be used for the food industry to produce 
several foods such as bread, beer, wine, distilled spirits, and industrial alcohols. The 
most knows are S. cerevisiae, S. boullardii, S. pombe, S. pastorianus, and S. para-
doxus, mostly used for food and treatments. Nevertheless, these yeasts have a small 
nucleus and central vacuole and have glucan and mannoproteins on their cell walls. 
Saccharomyces include a single linear double-stranded DNA, ribosomal proteins, 
and non-ribosomal molecules, like other eukaryotes. It was suggested that their 
genetic structure is beneficial for the model organism, especially S. cerevisiae [6].
Figure 1. 
Biomedical applications of yeasts.
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S. cerevisiae a single celled organism that is used as a model organism. These 
yeasts have been studied to understand the concept of cell cycle regulation, DNA 
repair, and other cellular mechanisms. It was also reviewed that a model to identify 
the mutations in the cell cycle in cancer and some diseases, especially neurodegen-
erative diseases [7]. However, a form of S. cerevisiae called S. boulardii had been 
observed in clinical trials for treatment such as inflammation and diarrhea. Mc 
Farland and Bernasconi reported that S. boulardii is a wild type of Saccharomyces, a 
pharmaceutical agent [8]. The action of S. boulardii has been described by releasing 
trypsin-like protease, which inhibits the toxins in inflammations [9].
Schizosaccharomyces pombe is a fission yeast that was isolated in 1893 by Paul 
Lindner from East African millet beer. It is a model organism for eukaryotic cell 
biology and molecular biology as well as S. boulardii and S. cerevisiae. In 1590, 
Mitchison was firstly studied with this yeast in an experimental organism. Eser et al. 
reported that it could be used to treat diabetes and other diseases [10]. This fission 
yeast has been studied for eukaryotic RNA metabolism due to its gene expression.
S. bayanus (S. eubayanus), S. paradoxus, and S. pastorianus have similar genome 
size with S. cerevisiae. They all have been studied for DNA reassociation studies 
[11]. S. pastorianus is a lager yeast, an interspecific hybrid between S. cerevisiae 
and another S. bayanus (S. eubayanus) [12]. It is also a synonym of S. carlsbergensis 
and closely related to genus S. cerevisiae. Another wild type of yeast, S. paradoxus, 
can be isolated from nature, especially tree exudates or oils. It is an essential type 
of yeast for genetic and genomic studies. A yeast named S. bayanus (S. eubayanus), 
which was isolated from the tree, is related to S. cerevisiae and S. pastorianus [13]. 
S. bayanus has been used for genomic studies, expression patterns, and nucleo-
somes profiles [14–16].
Saccharomyces yeasts focus on the dietary field as a probiotic and the process 
of treating the disease. Belong the probiotic action; these yeasts have several vital 
roles on mechanisms such as bacterial adhesion, enhancement of immune cells and 
responses, modulation of the signaling pathways of the host, and improvement 
of the strengthening of enterocytes [17]. Nevertheless, Saccharomyces are used as 
model organisms in biological studies, particularly chemicals and pharmaceuticals.
3. Experimental organism for pharmaceutical industry
Over the last fifty years, remarkable progress in our ability to produce advanced 
drugs has improved people’s health and longevity. Pharmaceutical proteins are one 
of the fastest-growing groups of medicines and are currently critical to treating 
many diseases [18].
Proteins have a catalyzer role in several metabolic reactions as well as an essen-
tial responsibility for cellular mechanisms. There are unique systems that can be 
used to produce proteins for the pharmaceutical industry from a single cell to mul-
tiple organisms, including eukaryotes, especially yeasts. Dozens of pharmaceutical 
proteins, including insulin, vaccines, and blood factors, produced by S. cerevisiae, 
have been commercialized. It was reviewed that yeasts are essential for biological 
activities, mainly producing the purified product due to its cost-effective, fast pro-
duction like bacteria and high density of cell cultures [19]. In recent years, indeed, 
as a model organism, yeasts have been provided to identify the pathogenesis and 
role for diseases, especially S. cerevisiae and S. pombe.
The yeast Saccharomyces has been accepted as the significant organism for 
several metabolisms such as cell cycle, biogenesis, protein folding, genetic manipu-
lation, recombination, etc. [20]. S. cerevisiae is a unicellular microbial organism 
that grows fast, tolerances to chemicals, and cultured easily. It was reported that 
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this yeast could discover the process of diseases because of the conservation of 
molecular interactions from yeast to humans [21, 22]. On the other hand, S. cerevi-
siae can be an essential organism for recombinant protein production for pharmacy. 
It has full cellular organelles and membrane compartments that produce many 
eukaryotic proteins, including humans’ [23]. Initially, the essential biopharma-
ceuticals insulin and its analogs have been produced by S. cerevisiae. Researchers 
have reported other important biopharmaceuticals such as the human serum 
albumin, hepatitis vaccines, and virus-like particles for vaccination (Table 1). 
Also, several medicines have been produced with S. cerevisiae until 2012 reported 
by the European Medicines Agency [18]. Furthermore, current studies showed that 
metabolic engineering pathways and optimization procedures of S. cerevisiae are 
essential for producing recombinant proteins for pharmaceuticals and biomedical 
areas [18, 19]. S. cerevisiae carries out human-like glycoprotein that is efficient for 
producing recombinant proteins. Protein secretion of S. cerevisiae is complex pro-
cessing that follows as transcription, translation, translocation, post-translational 
modifications, folding, peptide cleavage, glycosylation, sorting, and secretion. 
This important organism enables genetic modifications. It was reported that the 
first eukaryotic organism sequenced DNA in S. cerevisiae [41]. Due to the protein 
misfolding and aggregation, S. cerevisiae has been used as a model organism.
Nevertheless, S. pombe has been accepted as a model organism together with  
S. cerevisiae. This fission yeast is used as a successful host. It was reviewed that  
S. pombe and generated strains have significant facilitation for producing drug 
glucuronides [42, 43]. The classical yeast genetics approaches can be described for  
S. pombe. It has been accepted as the most ancient yeast molecule. However, S. pombe 
has been more advanced evolutionarily than other yeasts. S. pombe has become a 
model organism until 2002 [44, 45].
Recombinant proteins are recognized as an important part of the drug industry. 
Among these proteins, Saccharomyces has greater attention than others due to their 
eukaryotic properties, easy genetic manipulation, and capable of modifications. 
S. cerevisiae emerges as the most common host to express heterologous genes and 
therapeutic proteins [46]. This organism may provide a simple background for 
isotype expressions, and thereby drug metabolism studies can be easily associated 




Human serum albumin Blood 
factors
Payne et al. [24]
Recombinant proteins Protein Huang et al. [18], Ferrer-Millares et al. [19], Ma et al. [25], 
Cino [26]
Insulin Hormone Martinez et al. [27]
Glucagon Hormone Egel-Mitani et al. [28]
Human parathyroid 
hormone
Hormone Song et al. [29]
Purified protein for 
vaccines
Protein Hadiji-Abbes et al. [30], Zhang et al. [31], King et al. [32], 
Kaslow and Shiloach [33], Fazlalipour et al. [34].
Virus like particles Protein Jacobs et al. [35], Kim et al. [36], Kim et al. [37].
Gene expression systems Gene Malak et al. [38], van Ooyen et al. [39], Vierira Gomes  
et al. [40].
Table 1. 
Examples of bioparhamaceutical products of Saccharomyces.
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4. Antiviral strategies
While the vaccines currently available have proven invaluable in the fight against 
infectious diseases and eradicating viruses, there are many drawbacks to the current 
vaccine preparation or application regimen despite these successes. Certain limita-
tions of conventional vaccines require multiple adjuvants and injections to induce a 
necessary or optimal immune response. Another reason is the constant increase in 
the number of post-vaccination allergic reactions or hypersensitivities in a specific 
group of people [47, 48].
Today, there are several critical viral diseases such as human hepatitis B and C, 
immunodeficiency virus (HIV), severe acute respiratory syndrome coronavirus 
(SARS), coronavirus-disease 2019 (COVID19), etc. Due to the inadequacy of treat-
ment options for these infections, new antiviral strategies and model organisms, 
particularly yeast, were of interest to the researchers.
Yeasts have a delivery system for nucleic acids, and thus they can be an 
alternative for virus description. Besides, a humanized yeast system was identi-
fied for yeast/virus systems to study diseases [49]. Yeasts are used for subunit 
vaccine formulations with producing antigens against viruses. It was reviewed 
that yeast can be used for vaccine development in such strategies; whole 
recombinant yeast, virus-like particles, yeast display, and purified protein 
immunogens [50]. Among yeasts, S. cerevisiae has been accepted as a versatile 
model organism for viruses’ research, from the wire of public health to vaccine 
production.
Rosenfeld and Racaniello [51] reported that hepatitis C virus (HCV) was 
demonstrated in S. cerevisiae, and all proteins for the virus were encoded. Another 
study reported that S. cerevisiae could safely express the hepatitis B surface antigen 
in prophylactic vaccines [52]. Researchers observed that yeast could help clarify 
the function of viruses’ proteins with dissection of RNA viruses’ life cycle [53, 54]. 
Nevertheless, several protein immunogens can be purified from Saccharomyces. 
These immunogen proteins derived from yeasts are associated with virus-like par-
ticles. Virus-like particles can provide an alternative for viruses, and FDA approved 
this vaccine for hepatitis B and papillomavirus [55]. Also, the circumsporozoite 
protein derived from S. cerevisae is an immunodominant antibody of malaria. This 
preparation increased the antibodies and thereby neutralized the sporozoites [56]. 
Due to the yeast membrane permeability, S. cerevisiae enables entry to the chemical 
compounds and provides virus-host interactions. Some researchers showed that 
beta-glucan of the yeast cell wall could provide the immune response that impor-
tant for vaccine development [57].
All things considered, the yeast-based carrier system can be a potential model 
to develop the vaccine insights of virus-host interactions. The yeast strategies 
can improve the recognition of pathogen antigens peptides, activate the immune 
response, and also modulate the yeast-based vaccines. Researchers for further 
pioneering findings have still endured the studies.
5. Future perspectives
There have been many illnesses that have not been controlled by vaccination 
and new ones as well. Mutation, genetic exchange, environmental and interspecific 
transference, or human contact are the most emerging diseases. However, new 
scientific technologies, model organisms and a number of researchers have proven 
beneficial to vaccination strategies. In this respect, it is possible to observe yeasts for 
the upcoming vaccines for several diseases.
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Yeast engineered to the virus has been accepted as an ideal therapeutic approach. 
This vaccine’s strategy is improving humoral immunity due to the ability of yeast to 
the generation of immune responses.
There is a numerous increasing study to obtain the vaccine strategy of yeasts. 
Studies in yeast proteins and cell wall components, including beta-glucan, may 
become more critical for vaccine strategies under different phases of clinical trials 
on animals or humans. According to the essential features of yeast, the yeast-based 
vaccine strategy is being necessary for vaccine development. It has foreseen that 
diversity of yeast strains will improve in the future.
6. Conclusion
The yeast system provides invaluable antiviral strategies. Significant studies 
have been conducted on yeast progression in the identification of viral diseases and 
antiviral strategies. Based on a better understanding of yeast protein and viruses, 
the search for new vaccines and medications for viral or pandemic diseases is safer 
and more effective. However, experiments with animal models and human cells are 
still underway in many types of yeast. Knowledge of these new biological systems 
and technologies, models, and organisms will open up new science avenues.
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Acronyms and abbreviations
HIV  Human immunodeficiency virus
SARS  Severe Acute Respiratory Syndrome
COVID-2019  Coronavirus-disease 2019
FDA  U.S. Food and Drug Administration
DNA  Deoxyribonucleic acid
RNA  Ribonucleic acid
S. cerevisiae  Saccharomyces cerevisiae
S. boullardii  Saccharomyces boullardii
S. carlsbergensis  Saccharomyces carlsbergensis
S. bayanus  Saccharomyces bayanus
S. pastorianus  Saccharomyces pastorianus
S. paradoxus  Saccharomyces paradoxus
S. ebayanus  Saccharomyces ebayanus
S. pombe  Schizosaccharomyces pombe
Appendices and nomenclature
Yeast  The most important eukaryote; Saccharomyces.
Single celled organism Saccharomyces cerevisiae
Nucleosomes  DNA, RNA
Biopharmaceuticals insulin and its analogs
Eukaryotes    The organisms whose cells have a nucleus enclosed within 
a nuclear envelope
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Saraiva L. New insights into cancer-
related proteins provided by theyeast 
model. FEBS Journal. 2012;279:697-712. 
DOI: 10.1111/j.1742-4658.2012.08477.x
[21] Botstein D, Fink GR. Yeast: an 
experimental organism for modern 
biology. Science. 1988;240:1439-1443. 
DOI: 10.1126/science.3287619
[22] Smith MG, Snyder M. Yeast as a 
model for human disease. In: Curr 
Protoc Hum Genet. 2006. Chapter 
15:Unit 15.6. DOI: 10.1002/0471142905.
hg1506s48
[23] Nielsen J. Production of 
biopharmaceutical proteins by 




[24] Payne T, Finnis C, Evans LR,  
Mead DJ, Avery SV, Archer DB, 
Sleep D. Modulation of chaperone 
gene expression in mutagenized 
Saccharomyces cerevisiae strains 
developed for recombinant human 
albumin production results in increased 
production of multiple heterologous 
proteins. Appl Environ Microbiol. 
2008;74(24):7759-7766. DOI: 10.1128/
AEM.01178-08
[25] Ma JK, Drake PM, Christou P.  
The production of recombinant 
pharmaceutical proteins in plants. Nat 
Rev Genet. 2003;4(10):794-805. DOI: 
10.1038/nrg1177
[26] Cino J. High-yield protein 
production from Pichia pastoris yeast: 
a protocol for benchtop fermentation. 
Am Biotechnol Lab. 1999;17: 
10-21.
[27] Martinez JL, Liu LF, 
Petranovic D, Nielsen J. Pharmaceutical 
protein production by yeast: towards 
production of human blood proteins 
by microbial fermentation. Curr Opin 
Biotechnol. 2012;23(6):965-971. DOI: 
10.1016/j.copbio.2012.03.011
[28] Egel-Mitani M, Andersen AS,  
Diers II, Hach M, Thim L, 
Hastrup S, Vad K. Yield improvement 
of heterologous peptides expressed in 
yps1-disrupted Saccharomyces cerevisiae 
strains. Enzyme Microb Technol. 
2000;26(9-10):671-677. DOI: 10.1016/
s0141-0229(00)00158-7
[29] Song GY, Chung BH. 
Overproduction of human parathyroid 
hormone by fed-batch culture of a 
Saccharomyces cerevisiae mutant lacking 
yeast aspartic protease 3. Process 
Biochem. 1999;35(5):503-508. DOI: 
10.1016/S0032-9592(99)00097-7
[30] Hadiji-Abbes N, Martin M, Benzina W, 
Karray-Hakim H, Gergely C, Gargouri A, 
Mokhad-Gargouri R. Extraction and 
purification of hepatitis B virus-like 
M particles from a recombinant 
Saccharomyces cerevisiae strain using 





[31] Zhang L, Liu J, Lu J, Yan B, 
Song L, Li, L, Cui F, Zhang G, Wang F, 
Liang X, Xu A. Antibody response 
to revaccination among adult non-
responders to primary Hepatitis B 
vaccination in China. Hum Vaccin 
Immunother. 2015a;11:2716-2722. DOI: 
10.1080/21645515.2015.1045172
[32] King TH, Shanley CA, 
Guo Z, Bellgrau D, Rodell T, Furney S, 
Henao-Tamayo M, Orme IM. GI-19007, 
a novel Saccharomyces cerevisiae-based 
therapeutic vaccine against tuberculosis. 
Clin Vaccine Immunol. 2017;24:e00245–
e00217. DOI: 10.1128/CVI.00245-17
[33] Kaslow DC, Shiloach J. Production, 
purification and immunogenicity of a 
malaria transmission-blocking vaccine 
candidate: TBV25H expressed in yeast 
and purified using nickel-NTA agarose. 
Biotechnology (N Y). 1994;12:494-499. 
DOI: 10.1038/nbt0594-494
[34] Fazlalipour M, Keyvani H, 
Monavari SH, Mollaie HR. Expression, 
purification and immunogenic 
description of a hepatitis C virus 
recombinant CoreE1E2 protein 
expressed by yeast Pichia pastoris. 
Jundishapur J Microbiol. 2015;8:e17157. 
DOI: 10.5812/jjm.8(4)2015.17157
[35] Jacobs E, Rutgers T, Voet P, 
Dewerchin M, Cabezon T, de Wilde M. 
Simultaneous synthesis and assembly 
of various hepatitis B surface 
proteins in Saccharomyces cerevisiae. 
Gene 1989;80:279-291. DOI: 
10.1016/0378-1119(89)90292-8
[36] Kim HJ, Kim SY, Lim SJ,  
Kim JY, Lee SJ, Kim HJ. One-step 
chromatographic purification of human 
papillomavirus type 16 L1 protein 
from Saccharomyces cerevisiae. Protein 
Expression Purif. 2010;70:68-74. DOI: 
10.1016/j.pep.2009.08.005
[37] Kim HJ, Lee JY, Kang HA,Lee Y, 
Park EJ, Kim HJ. Oral immunization 
with whole yeast producing viral capsid 
antigen provokes a stronger humoral 
immune response than purified viral 
capsid antigen. Lett Appl Microbiol. 
2014;58:285-291. DOI: 10.1111/
lam.12188
[38] Malak A, Baronian K, Kunze G. 
Blastobotrys (Arxula) adeninivorans: 
a promising alternative yeast for 
biotechnology and basic research. Yeast. 
2016;33:535-547. DOI: 10.1002/yea.3180
[39] van Ooyen AJ, Dekker P, 
Huang M, Olsthoorn MMA, Jacobs DI, 
Colussi PA, Taron CH. Heterologous 
protein production in the yeast 
Kluyveromyces lactis. FEMS 
Yeast Res. 2006;6:381-392. DOI: 
10.1111/j.1567-1364.2006.00049.x
[40] Vieira Gomes AM, Souza Carmo T, 
Silva Carvalho L, Mendonça Bahia F, 
Skorupa Parachin N. Comparison of 
yeasts as hosts for recombinant 
protein production. Microorganisms. 
2018;6(2):38. OI: 10.3390/
microorganisms6020038
[41] Goffeau A, Barrell BG,  
Bussey H, Davis RW, Dujon B, 
Feldmann H, Galibert F, Hoheisel JD, 
Jacq C, Johnston M, Louis EJ, Mewes HW, 
Murakami Y, Philippsen P, Tettelin H, 
Oliver SG. Life with 6000 genes. Science. 
1996;274(5287):546, 563-547. DOI: 
10.1126/science.274.5287.546
[42] Giga-Hama Y, Kumagai H. 
Expression system for forein genes using 
the fission yeast Schizosaccharomyces 
pombe. Biotechnology and Applied 
Biochemistry. 2000;30(3):235-244. DOI: 
10.1111/j.1470-8744.1999.tb00776.x
[43] Drăgan CA, Buchheit D,  
Bischoff D, Ebner T, Bureik M. 
Glucuronide production by whole-
cell biotransformation using 
genetically engineered fission yeast 
11
Saccharomyces: Is a Necessary Organism or a Biological Warrior?
DOI: http://dx.doi.org/10.5772/intechopen.96029
Schizosaccharomyces pombe. Drug 
Metab Dispos. 2010;38(3):509-515. doi: 
10.1124/dmd.109.030965
[44] Wood V, Gwilliam R, Rajandream MA, 
Lyne M, Lyne R, Stewart A, Sgouros J, 
Peat N, Hayles J, Baker S, Basham D, 
Bowman S, Brooks K, Brown D, Brown S, 
Chillingworth T, Churcher C, Collins M, 
Connor R, Cronin A, Davis P, Feltwell T, 
Fraser A, Gentles S, Goble A, Hamlin N, 
Harris D, Hidalgo J, Hodgson G, Holroyd S, 
Hornsby T, Howarth S, Huckle EJ, Hunt S, 
Jagels K, James K, Jones L, Jones M, 
Leather S, McDonald S, McLean J, 
Mooney P, Moule S, Mungall K, Murphy L, 
Niblett D, Odell C, Oliver K, O'Neil S, 
Pearson D, Quail MA, Rabbinowitsch E, 
Rutherford K, Rutter S, Saunders D, 
Seeger K, Sharp S, Skelton J, Simmonds M, 
Squares R, Squares S, Stevens K, Taylor K, 
Taylor RG, Tivey A, Walsh S, Warren T, 
Whitehead S, Woodward J, Volckaert G, 
Aert R, Robben J, Grymonprez B, 
Weltjens I, Vanstreels E, Rieger M, 
Schäfer M, Müller-Auer S, Gabel C, 
Fuchs M, Düsterhöft A, Fritzc C, Holzer E, 
Moestl D, Hilbert H, Borzym K, Langer I, 
Beck A, Lehrach H, Reinhardt R, Pohl TM, 
Eger P, Zimmermann W, Wedler H, 
Wambutt R, Purnelle B, Goffeau A, 
Cadieu E, Dréano S, Gloux S, Lelaure V, 
Mottier S, Galibert F, Aves SJ, Xiang Z, 
Hunt C, Moore K, Hurst SM, Lucas M, 
Rochet M, Gaillardin C, Tallada VA, 
Garzon A, Thode G, Daga RR, Cruzado L, 
Jimenez J, Sánchez M, del Rey F, Benito J, 
Domínguez A, Revuelta JL, Moreno S, 
Armstrong J, Forsburg SL, Cerutti L, 
Lowe T, McCombie WR, Paulsen I, 
Potashkin J, Shpakovski GV, Ussery D, 
Barrell BG, Nurse P. The genome sequence 
of Schizosaccharomyces pombe. Nature. 
2002;415:871-880. DOI: 10.1038/
nature724
[45] Hoffman CS, Wood V, Fantes PA. 
An ancient yeast for young geneticists: 
A primer on the Schizosaccharomyces 
pombe model system. Genetics. 
2015;201:403-423. DOI: 10.1534/
genetics.115.181503
[46] Darby RA, Cartwright SP, 
Dilworth MV, Bill RM. Which yeast 
species shall I choose? Saccharomyces 
cerevisiae versus Pichia pastoris 
(review). Methods Mol 
Biol. 2012;866:11-23. DOI: 
10.1007/978-1-61779-770-5_2
[47] Shams H. Recent developments 
in veterinary vaccinology. Vet J. 
2005;170(3):289-299. DOI: 10.1016/j.
tvjl.2004.07.004
[48] Fang Y, Liu MQ, Chen L, 
Zhu ZG, Zhu RZ, Hu Q. Rabies post-
exposure prophylaxis for a child 
with severe allergic reaction to 
rabies vaccine. Hum Vaccin 
Immunother 2016;12:1802-1804. DOI: 
10.1080/21645515.2016.1143158
[49] Mager WH, Winderickx J. Yeast 
as a model for medical and medicinal 
research. Trends Pharmacol Sci. 
2005;26:265-273. DOI: 10.1016/j.
tips.2005.03.004
[50] Kumar R, Kumar P. Yeast-based 
vaccines: New perspective in vaccine 
development and application. FEMS 
Yeast Research. 2019;19. DOI: 10.1093/
femsyr/foz007
[51] Rosenfeld AB, Racaniello VR. 
Hepatitis C virus internal ribosome 
entry site-dependent translation 
in Saccharomyces cerevisiae is 
independent of polypyrimidine tract-
binding protein, poly(rC)-binding 
protein 2, and La protein 1. J Virol. 
2005;79:10126-10137. DOI: 10.1128/
JVI.79.16.10126-10137.2005
[52] Valenzuela P, Medina A, Rutter WJ, 
Ammerer G, Hall BD. Synthesis and 
assembly of hepatitis B virus 
surface antigen particles in yeast. 
Nature. 1982;298:347-350. DOI: 
10.1038/298347a0
[53] Blanco R, Carrasco L, Ventoso I. Cell 





[54] Kapoor P, Lavoie BD, Frappier L. 
EBP2 plays a key role in Epstein-Barr 
virus mitotic segregation and is 
regulated by aurora family kinases. 
Mol Cell Biol. 2005;25:4934-4945. DOI: 
10.1128/MCB.25.12.4934-4945.2005
[55] Zhang X, Xin L, Li S, Fang M, 
Zhang J, Xia N, Zhao Q. Lessons learned 
from successful human vaccines: 
delineating key epitopes by dissecting 
the capsid proteins. Hum Vaccine 
Immunotherapeutics 2015;11:1277-1292. 
DOI: 10.1080/21645515.2015.1016675
[56] Nussenzweig V, Barr P, inventors; 
New York University, Chiron 
Corporation, assignee. Vaccine against 
the sporozoite stage of malaria. Patent 
US4997647A. 1991.
[57] Karumuthil-Melethil S, Gudi R, 
Johnson BM, Perez N, Vasu C. Fungal 
βglucan, a Dectin-1 ligand, promotes 
protection from type 1 diabetes by 
inducing regulatory innate immune 
response. J Immunol 2014;193:3308-
3321. DOI: 10.4049/jimmunol.1400186
